Expertise in
2
conditions

Roberto P. Cid

Zaragoza, AR, ES 
Expertise in
2
conditions
Zaragoza, AR, ES 

Overview

Roberto Cid practices practicing medicine in Zaragoza, Spain.

Mr. Cid is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Stomach Cancer, and Esophageal Cancer.

He is actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Zaragoza, AR, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drug: ZW25 (Zanidatamab)
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

8 Total Publications

The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors.
The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors.
Journal: ESMO gastrointestinal oncology
Published: August 12, 2026

Frequently Asked Questions about Roberto P. Cid

Is Roberto P. Cid a top-rated expert for Pancreatic Ductal Adenocarcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Roberto P. Cid is classified as an Advanced expert for Pancreatic Ductal Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Roberto P. Cid participate in research or clinical trials?

Yes. Roberto P. Cid has published 8 articles and abstracts on conditions like Pancreatic Ductal Adenocarcinoma. You can view a list of Roberto P. Cid's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cid's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile